Helus Pharma (HELP) has priced an underwritten public offering of 10.3 million common shares at $4.85 apiece for aggregate gross proceeds of $50 million, the company said Wednesday.
The company said it will use the proceeds to advance its HLP003, HLP004 and HLP005 programs, including HLP003 for major depressive disorder, with phase 3 data expected in the fourth quarter.
The offering is expected to close Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.